Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

New antitumor compounds from Schering-Plough act by inhibiting protein farnesyltransferase

Sep. 30, 1999

Long-term efficacy and tolerability reported for MTX-HSA in preliminary clinical testing

Sep. 30, 1999

Northwest Biotherapeutics and Battelle form prostate cancer collaboration

Sep. 30, 1999

Cell Pathways and RPR to study Aptosyn in combination with Taxotere

Sep. 30, 1999

Hybridon presents HYB-165, the first orally active antitumor oligonucleotide

Sep. 30, 1999

EntreMed's first phase I study of Endostatin now enrolling patients

Sep. 29, 1999

IntraDose featured in several ECCO 10 presentations; clinical results consistently positive

Sep. 29, 1999

New prescribing information for flutamide

Sep. 29, 1999

ECCO 10 presentation for a novel VEGF receptor TK inhibitor

Sep. 29, 1999

Protein farnesyltransferase inhibitors developed at Schering-Plough

Sep. 29, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...